AstraZeneca PLC (AZN)vsLENZ Therapeutics Inc (LENZ)
AZN
AstraZeneca PLC
$166.27
-1.05%
HEALTHCARE · Cap: $263.12B
LENZ
LENZ Therapeutics Inc
$4.81
+0.63%
HEALTHCARE · Cap: $147.05M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 285656% more annual revenue ($61.37B vs $21.48M). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
LENZ
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.3%
Fair Value
$196.36
Current Price
$166.27
$30.09 discount
Intrinsic value data unavailable for LENZ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.44 suggests the stock is reasonably priced for its growth.
Bull Case : LENZ
The strongest argument for LENZ centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : LENZ
The primary concerns for LENZ are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while LENZ is a value play — different risk/reward profiles.
LENZ carries more volatility with a beta of 1.63 — expect wider price swings.
LENZ is growing revenue faster at 9.7% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 35/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
LENZ Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders, specifically targeting critical unmet needs in the central nervous system (CNS). The company employs advanced drug formulation and delivery technologies to support a robust pipeline of proprietary assets, aiming to enhance patient outcomes and address significant healthcare challenges. With a strong focus on strategic partnerships and a commitment to rigorous clinical research, LENZ is strategically positioned for significant growth and aspires to become a key player in the biopharmaceutical landscape, leveraging emerging opportunities in the dynamic healthcare market.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?